In English | En español

National Cancer Institute

at the National Institutes of Health

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI

Clinical Trials Search Results

Page Options

Email This Document

Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Popular Resources

Help Using the NCI Clinical Trials Search Form
Learn About Clinical Trials
About NCI's List of Cancer Clinical Trials
NCI Dictionary of Cancer Terms
NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 38 for your search:

Drug:  MART-1 antigen
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Vaccine Therapy and/or Sargramostim in Treating Patients With Locally Advanced or Metastatic Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000067568, U10CA021115, ECOG-4697, SWOG-E4697, E4697, NCT00005034

Phase I/II Study of Immunization With Dendritic Cells Presenting Epitopes Derived from the Melanoma Associated Antigens MART-1 and gp100 With or Without Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-97-C-0046, NCI-97-C-0019, NCI-T96-0046N, T96-0046, NCT00019214

Vaccine Therapy and Interleukin-12 in Treating Patients With Metastatic Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: CDR0000065424, UCCRC-9018, UCCRC-8381, NCI-G97-1162, NCT00002952

Phase I/II Study of Ad2/MART-1v2 and Ad2/gp100v2 Melanoma Antigen Vaccines in Patients With Stage II, III, or IV Melanoma (Summary Last Modified 07/2002)

Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: GENZ-ADVMEL-001-99, DFCI-00069, GENZ-2000-P-000380/1, NCT00010309

Phase II Study of Immunization Comprising Immunodominant Peptides from 3 Melanoma Antigens (MART-1, gp100, and Tyrosinase) in Patients With Refractory Metastatic Melanoma (Summary Last Modified 10/2000)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-98-C-0023, NCI-T97-0089, T97-0089

Phase II Study of Flt3 Ligand Alone or in Combination With Melanoma Peptide Immunization in Patients With Metastatic Melanoma or Renal Cell Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: NCI-98-C-0040, NCI-T97-0092, T97-0092, NCT00019396

Phase II Study of MART-1 and gp100 Peptides Modified to Increase Binding to HLA-A0201 With or Without Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-99-C-0092, NCI-T99-0033, T99-0033, NCT00019721

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 990158, 99-C-0158, NCI-99-C-0158, NCI-T99-0078, T99-0078, NCT00019942, NCT00001832

Phase II Study of Immunization Using gp100:44-59, gp100:209-217 (210M), and MART-1:26-35 (27L) Antigen Peptides in HLA-DRB1*0401 Positive Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-99-C-0159, NCI-T99-0079, T99-0079, NCT00019994

10.

Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M991, NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

11.

Phase II Randomized Study of Immunization With an HLA-A2 Multiepitope Peptide Vaccine Comprising MART-1:27-35, gp100:209-217 (210M), and Tyrosinase:368-376 (370D) Peptides Alone or in Combination With Sargramostim (GM-CSF) and/or Interferon alfa-2b in HLA-A2 Positive Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1696, NCT00006385, E1696

12.

Phase II Study of gp100:209-217 (210M) Antigen and MART-1:26-35 (27L) Antigen Emulsified in Montanide ISA-51 in Patients With Metastatic Ocular Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: NCI-01-C-0074, NCI-2910, 2910, NCT00020475

13.

Phase II Randomized Adjuvant Study of Vaccination With Tyrosinase, gp100, and MART-1 Peptides Emulsified With Montanide ISA-51 With Interleukin-12 and Either Alum Adjuvant or Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M011, LAC-USC-IRB-013030, NCI-5506, NCT00031733, 5506

14.

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 16 and over
Sponsor: NCI
Protocol IDs: 030172, 03-C-0172, NCI-03-C-0172, NCI-6211, 6211, NCT00062218, NCT00059475

15.

Phase II Randomized Study of Immunization With MAGE-3, Melan-A, gp100 Antigen, and NA17-A Peptide-Pulsed Autologous Peripheral Blood Mononuclear Cells and Interleukin-12 With or Without Low-Dose Interleukin-2 in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-11447A, NCI-1330, NCT00064168, 1330

16.

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: CDR0000365467, P30CA076292, P30CA014089, MCC-15241, MDX010-16, NCI-6446, CA184-016, 6446, LAC-USC-10M036, NCT00084656

17.

Phase II Randomized Continuation Study of a Vaccine Comprising Tyrosinase Peptide, gp100 Antigen, and MART-1 Antigen Emulsified With Montanide ISA-51 and ISA-51 VG With or Without Sargramostim (GM-CSF) in Patients With Resected Stage IIB, IIC, III, or IV Melanoma

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M038, LAC-USC-042011, LAC-USC-0A1033, NCI-6618, 6618, NCT00089063

18.

Phase II Randomized Study of Vaccination Comprising gp100 and MART-1 Peptide Vaccines Emulsified in Montanide ISA-51 With or Without High-Dose Interleukin-2 After Lymphodepleting Chemotherapy and Reinfusion of Autologous T-Regulatory-Depleted Lymphocytes in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0028, 7547, NCI-7547, NCI-P6574, NCT00303836

19.

Phase II Study of Recombinant LMB-2 Immunotoxin and Peptide Vaccination Comprising gp100:209-217 (210M) Antigen, MART-1:27-35 Antigen, and Montanide ISA-51 in Patients With Progressive Unresectable Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-06-C-0041, 7542, NCI-7542, NCI-P6702, NCT00295958

20.

Phase II Study of MART-1/gp100/Tyrosinase Peptide-Pulsed Dendritic Cell Vaccine Matured With a Cytokine Cocktail in Patients With Metastatic Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI
Protocol IDs: LAC-USC-10M-03-1, 6262, NCI-6262, LAC-USC-033307, NCT00334776

21.

Phase I Study of Immunization with Recombinant Fowlpox Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 01/00)

Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-95-C-0032D, NCI-T96-0026N, T96-0026

22.

Phase I Study of MART-1 Human Melanoma Peptide Vaccine in Metastatic Melanoma (Summary Last Modified 01/2000)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0071C, NCI-T94-0178N, T94-0178

23.

Phase I Study of Immunization with Recombinant Vaccinia Virus Encoding the MART-1 Melanoma Antigen with or without Concomitant IL-2 in Patients with Metastatic Melanoma (Summary Last Modified 03/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-95-C-0068C, NCI-T94-0137N, T94-0137

24.

Phase I Study of Immunization with Adenovirus Encoding the MART-1 Melanoma Antigen for Refractory Metastatic Melanoma (Summary Last Modified 12/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0079D, NCI-T94-0195N, T94-0195

25.

Phase I Study of IL-12 Administered with a MART-1 Peptide Vaccine in Patients with Refractory Metastatic Melanoma (Summary Last Modified 11/1999)

Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-95-C-0143B, NCI-T95-0039N, T95-0039

Select All on Page

Help with Results

We Can Answer Your Questions
1-800-4-CANCER
LiveHelp Online Chat

NCI Home
Contact Us
Policies
Accessibility
Viewing Files
FOIA
Site Help
Site Map

Other Versions of this Site: Mobile | Español

Follow Us:

Twitter
YouTube
Facebook
RSS

NIH…Turning Discovery Into Health^®